Tag: huntingtons disease treatment market forecast

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Huntington’s Disease Treatment Market Size, Value And Growth Trajectory Through 2030

The huntington’s disease treatment market size has experienced rapid growth in recent years. It is anticipated to expand from $0.82 billion in 2025 to $0.92 billion in 2026, at a compound annual growth rate (CAGR) of 12.6%. This historical growth can be attributed to several factors including limited treatment options for neurodegenerative disorders, an increasing diagnosis of genetic neurological diseases, early reliance on symptomatic management, the expansion of neurology specialty care, and growth in hospital-based neurological treatments.

The huntington’s disease treatment market is projected for significant expansion in the coming years. It is anticipated to reach $1.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. This expansion throughout the forecast period can be attributed to several factors, including breakthroughs in gene therapy technologies, increased investment in rare disease research, a rise in orphan drug designations, the growing acceptance of precision medicine, and a broader pipeline of disease-modifying therapies. Key trends expected during this period involve an increasing focus on disease-modifying treatments, wider adoption of gene and RNA-based therapies, the expansion of combination therapy strategies, a heightened emphasis on developing symptom-specific drugs, and a surge in clinical trial activities for rare neurological conditions.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=24273179&type=smp&name=Huntington%E2%80%99s%20Disease%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Huntington’s Disease Treatment Market Growth Drivers: What’s Behind The Acceleration?

The rising prevalence of gene therapies is anticipated to significantly advance the Huntington’s disease treatment market in the coming years. Gene therapies are therapeutic approaches designed to modify or substitute impaired genes, aiming to alleviate or avert diseases at their fundamental genetic origin. Their expansion is fueled by advancements in precision medicine, allowing for direct targeting of genetic anomalies and yielding superior results compared to conventional remedies. For Huntington’s disease, gene therapies function by silencing the malfunctioning HTT gene, which is responsible for producing detrimental proteins, thereby safeguarding nerve cells from damage. This methodology contributes to decelerating disease progression, preserving brain function, and offers prospects for sustained management. As an illustration, data from July 2023, compiled by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, indicated that 247 gene therapies were in phase II at the close of Q1 2023. This figure subsequently increased by 5%, reaching 260 by the conclusion of Q2. Consequently, the expanding landscape of gene therapies is serving as a key impetus for the expansion of the Huntington’s disease treatment market.

Huntington’s Disease Treatment Market Breakdown By Product Type And Application

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Huntington’s Disease Treatment Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies within the Huntington’s disease treatment market are concentrating on developing innovative therapies, including selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the goal of potentially enhancing patient quality of life and slowing disease progression. Selective VMAT2 inhibitor capsules are medicines that work by blocking vesicular monoamine transporter 2, a protein responsible for packaging neurotransmitters for release in the brain. These drugs contribute to reducing neurotransmitter release, which helps in managing involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, secured approval from the U.S. Food and Drug Administration (FDA) for its Ingrezza (valbenazine) capsules, intended for treating chorea associated with Huntington’s disease (HD) in adults. These capsules represent a once-daily oral VMAT2 inhibitor that functions by diminishing excessive dopamine signaling in the brain to help regulate involuntary movements. The medication is provided in various capsule strengths and can be consumed either with or without food, presenting a flexible dosing solution for patients.

Huntington’s Disease Treatment Market Company Landscape And Competitive Strategy

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.

View The Full Huntington’s Disease Treatment Market Report:

https://thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Huntington’s Disease Treatment Market Geographic Distribution And Regional Opportunities

North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Huntington’s Disease Treatment Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The market for Huntington’s disease treatments has experienced rapid expansion over the last few years. Valued at $0.82 billion in 2025, it is projected to reach $0.92 billion by 2026, reflecting a compound annual growth rate (CAGR) of 12.6%. This historic period of growth has been driven by several key factors: the scarcity of therapies for neurodegenerative conditions, a rise in diagnoses of genetic neurological disorders, an initial dependence on symptom management, the broadening of specialized neurology care, and an increase in treatments administered within hospital settings for neurological issues.

The huntington’s disease treatment market is projected to undergo substantial expansion over the coming years. By 2030, it is forecasted to reach $1.48 billion, reflecting a compound annual growth rate (CAGR) of 12.6%. This anticipated growth during the forecast period is driven by progress in gene therapy technologies, heightened funding for rare disease research, a greater number of orphan drug designations, wider implementation of precision medicine, and a more robust pipeline of disease-modifying therapies. Key developments shaping this period include a stronger focus on disease-modifying treatments, greater utilization of gene and RNA-based therapies, the rise of combination therapy strategies, increased attention to drugs targeting specific symptoms, and a surge in clinical trials for rare neurological conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Huntington’s Disease Treatment Market Development Factors: Which Trends Are Supporting Demand?

The expansion of gene therapies is anticipated to drive forward the growth of the Huntington’s disease treatment market in the coming period. These therapeutic approaches work by modifying or replacing defective genes to address or prevent illnesses at the genetic level. With advancements in precision medicine, gene therapies are gaining traction as they allow for the direct targeting of genetic causes, yielding more effective results compared to conventional treatments. In the context of Huntington’s disease, such therapies function by silencing the faulty HTT gene, which is responsible for producing harmful proteins, thereby preventing damage to nerve cells. This method contributes to slowing the advancement of the disease, safeguarding brain function, and offering the possibility of sustained management over time. For example, data from the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the US, and Citeline, a US-based provider of drugs and devices, indicates that as of the end of the first quarter in 2023, there were 247 gene therapies in phase II, with this number increasing by 5% to reach 260 by the conclusion of the second quarter. Consequently, the rise in gene therapies is fueling the expansion of the Huntington’s disease treatment market.

Huntington’s Disease Treatment Market Segment Landscape And Growth Potential

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Huntington’s Disease Treatment Market Transformation Trends: Which Innovations Are Driving Change?

Key players in the market for Huntington’s disease treatments are concentrating on creating sophisticated therapies, including selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the goal of enhancing patients’ quality of life and decelerating the condition’s progression. These selective VMAT2 inhibitor capsules function by obstructing the vesicular monoamine transporter 2, a protein crucial for packaging neurotransmitters for release within the brain. By decreasing neurotransmitter output, these medications assist in alleviating uncontrolled movements and associated symptoms. In August 2023, for example, Neurocrine Biosciences, Inc., a biotechnology firm based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for its Ingrezza (valbenazine) capsules, specifically indicated to treat chorea linked to Huntington’s disease (HD) in adults. Designed as a once-daily oral VMAT2 inhibitor, this medication works by lowering excessive dopamine signaling in the brain to better regulate involuntary motions. Available in multiple dosage strengths, these capsules may be taken with or without food, providing a practical and flexible administration choice for those affected.

Huntington’s Disease Treatment Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.

Access The Complete Huntington’s Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Huntington’s Disease Treatment Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Huntington’s Disease Treatment Market Increase Between 2026 And 2030?

The Huntington’s disease treatment market has experienced rapid expansion in recent years. This market is projected to expand from $0.82 billion in 2025 to $0.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.6%. Historically, this growth can be attributed to several factors, including the scarcity of treatment alternatives for neurodegenerative conditions, a rise in the diagnosis of genetic neurological illnesses, an initial focus on managing symptoms, the broadening of neurology specialty healthcare services, and an increase in neurological treatments provided in hospitals.

The huntington’s disease treatment market is projected for significant expansion over the coming years. It is anticipated to reach $1.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.6%. This expansion during the forecast period is driven by progress in gene therapy technologies, increased funding for rare disease research, more orphan drug designations, the growing embrace of precision medicine, and a broader array of disease-modifying therapies in development. Key developments expected during this period include an intensified focus on disease-modifying treatments, wider use of gene and RNA-based therapies, broader application of combination treatment strategies, a greater emphasis on developing symptom-specific drugs, and heightened clinical trial activity for uncommon neurological conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

What Influential Factors Are Boosting The Huntington’s Disease Treatment Market Demand?

The Huntington’s disease treatment market is anticipated to expand due to the rising adoption of gene therapies. These therapies involve altering or substituting defective genes to prevent or treat illnesses at their fundamental genetic origin. The progression of precision medicine is fueling the expansion of gene therapies, allowing them to precisely target genetic root causes and deliver superior results compared to conventional approaches. In the context of Huntington’s disease, gene therapies work by deactivating the faulty HTT gene, which is responsible for producing detrimental proteins, thereby averting damage to nerve cells. This method aids in decelerating the disease’s advancement, preserving brain capabilities, and presents a prospect for sustained management. An illustration of this trend is seen in data from July 2023, released by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, which indicated that while there were 247 gene therapies in phase II at the close of Q1 2023, this figure increased by 5% to 260 by the end of Q2. Consequently, the expanding availability of gene therapies is stimulating the expansion of the Huntington’s disease treatment market.

How Are Different Segment Groups Identified Within The Huntington’s Disease Treatment Market?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Which Trends Are Supporting The Evolution Of The Huntington’s Disease Treatment Market?

Leading enterprises in the Huntington’s disease treatment market are concentrating on the development of advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the aim of potentially enhancing patients’ quality of life and decelerating disease progression. Selective VMAT2 inhibitor capsules are medications designed to block the vesicular monoamine transporter 2, a protein essential for packaging neurotransmitters prior to their release in the brain. These drugs contribute to reducing neurotransmitter release, thereby assisting in the management of involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, secured approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules for addressing chorea associated with Huntington’s disease (HD) in adults. These capsules represent a once-daily oral VMAT2 inhibitor, which functions by mitigating excessive dopamine signaling in the brain to aid in controlling involuntary movements. The medication is offered in multiple capsule strengths and can be taken either with or without food, presenting a practical dosing choice for patients.

Who Are The Firms Contributing To The Huntington’s Disease Treatment Market Ecosystem?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.

Access The Complete Huntington’s Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

Which Region Leads The Huntington’s Disease Treatment Market By Size?

North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Huntington’s Disease Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2026, By The Business Research Company

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Huntington’s Disease Treatment Market In 2026 And 2030?

The huntington’s disease treatment market size has expanded rapidly in recent years. It is projected to increase from $0.82 billion in 2025 to $0.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. The historical growth of this market can be attributed to several factors including limited treatment options for neurodegenerative disorders, a rise in the diagnosis of genetic neurological diseases, an early focus on symptomatic management, the expansion of neurology specialty care, and an increase in hospital-based neurological treatments.

The huntington’s disease treatment market size is anticipated to undergo significant expansion in the upcoming years. It is predicted to attain a value of $1.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. The expansion foreseen during this period can be ascribed to breakthroughs in gene therapy technologies, a rise in funding for rare disease research, an increase in orphan drug designations, greater embrace of precision medicine, and a growing array of disease-modifying therapies in development. Noteworthy trends for the forecast period include an intensified focus on disease-modifying treatments, wider acceptance of gene and RNA-based therapies, broader implementation of combination therapy approaches, an increasing emphasis on creating symptom-specific drugs, and a surge in clinical trial activity for uncommon neurological disorders.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

What Factors Are Contributing To The Growth Of The Huntington’s Disease Treatment Market?

The expanding presence of gene therapies is anticipated to drive the future growth of the Huntington’s disease treatment market. These therapies involve modifying or replacing flawed genes to prevent or cure illnesses at a genetic level. Their development is accelerating with advancements in precision medicine, allowing for direct targeting of genetic origins and yielding superior results compared to conventional treatments. Specifically for Huntington’s disease, gene therapies function by inactivating the faulty HTT gene, which produces harmful proteins, thereby averting damage to nerve cells. This approach contributes to slowing the disease’s progression, safeguarding brain function, and offers prospects for enduring management. For instance, data from July 2023, provided by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, indicated that 247 gene therapies were in phase II at the close of Q1 2023, a figure that climbed by 5% to reach 260 by the end of Q2. Consequently, the rising number of gene therapies is propelling the expansion of the Huntington’s disease treatment market.

What Segment Categories Shape The Huntington’s Disease Treatment Market Segment Landscape?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

What Trends Are Shaping The Future Of The Huntington’s Disease Treatment Market?

Leading companies within the Huntington’s disease treatment market are concentrating on developing advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the aim of potentially enhancing patient quality of life and decelerating disease progression. These selective VMAT2 inhibitor capsules are medications designed to obstruct vesicular monoamine transporter 2, a protein crucial for packaging neurotransmitters before their release in the brain. By reducing neurotransmitter release, these drugs assist in managing involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotechnology company, secured approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules, intended for the treatment of chorea associated with Huntington’s disease (HD) in adults. These capsules function as a once-daily oral VMAT2 inhibitor, operating by diminishing excessive dopamine signaling in the brain to help regulate involuntary movements. The medication is provided in multiple capsule strengths and can be administered with or without food, thereby offering a convenient dosing option for patients.

Who Are The Companies Operating Across The Huntington’s Disease Treatment Market Value Chain?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.

Get The Full Huntington’s Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

Which Geographic Region Dominates The Huntington’s Disease Treatment Market?

North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Huntington’s Disease Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2026, By The Business Research Company

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Huntington’s Disease Treatment Market During The Forecast Period 2026–2030?

The Huntington’s disease treatment market has witnessed rapid growth in recent years. It is projected to expand from $0.82 billion in 2025 to $0.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. The historical surge in this market can be attributed to several factors: restricted treatment options for neurodegenerative disorders, an increased rate of diagnosis for genetic neurological diseases, an early focus on symptomatic management, the widening availability of neurology specialty care, and an expansion in hospital-based neurological treatments.

The Huntington’s disease treatment market is poised for substantial growth in the upcoming years. It is expected to reach $1.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. This anticipated expansion during the forecast period is fueled by advancements in gene therapy technologies, increasing investment in rare disease research, a rise in orphan drug designations, the growing adoption of precision medicine, and an expanding pipeline of disease-modifying therapies. Dominant trends during this period encompass an increasing focus on disease-modifying treatments, broader integration of gene and RNA-based therapies, the proliferation of combination therapy approaches, an elevated emphasis on symptom-specific drug development, and increased clinical trial activity for rare neurological disorders.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

What Underlying Factors Are Accelerating The Growth Of The Huntington’s Disease Treatment Market?

The growing availability of gene therapies is anticipated to drive the expansion of the Huntington’s disease treatment market moving forward. These treatments involve modifying or replacing faulty genes to address or prevent diseases at their genetic origin. Gene therapies are advancing due to developments in precision medicine, allowing for the direct targeting of genetic causes and leading to improved outcomes compared to conventional treatments. In the context of Huntington’s disease, gene therapies function by silencing the defective HTT gene responsible for producing harmful proteins, thereby preventing damage to nerve cells. This approach aids in slowing disease progression, preserving brain function, and offers potential for long-term control. For example, in July 2023, reports from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, showed that 247 gene therapies were in phase II at the end of Q1 2023, a figure that climbed by 5% to 260 by the end of Q2. Thus, the rise in gene therapies is fueling the growth of the Huntington’s disease treatment market.

What Market Segments Are Evaluated Within The Huntington’s Disease Treatment Market?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

What Industry Trends Are Redefining The Huntington’s Disease Treatment Market?

Leading companies in the Huntington’s disease treatment market are concentrating on developing advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, to potentially enhance patient quality of life while slowing disease progression. Selective VMAT2 inhibitor capsules are medications designed to block the vesicular monoamine transporter 2, a protein instrumental in packaging neurotransmitters for brain release. These drugs aid in reducing neurotransmitter release, thereby assisting in the management of involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, obtained approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules, indicated for the treatment of chorea associated with Huntington’s disease (HD) in adults. These capsules represent a once-daily oral VMAT2 inhibitor that functions by decreasing excessive dopamine signaling in the brain to help regulate involuntary movements. The medication is accessible in various capsule strengths and can be consumed with or without food, presenting a convenient dosing alternative for patients.

Who Are The Top Market Participants Influencing The Huntington’s Disease Treatment Market?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.

Read the full huntington’s disease treatment market report here:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

Which Region Is Projected To Dominate The Huntington’s Disease Treatment Market During The Forecast Period?

North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Huntington’s Disease Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2026, By The Business Research Company

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the huntington’s disease treatment market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Huntington’s Disease Treatment Market between 2026 and 2030?

The huntington’s disease treatment market size has seen rapid expansion in recent years. It is anticipated to increase from $0.82 billion in 2025 to $0.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. This historical growth can be linked to several factors, including the limited availability of treatment options for neurodegenerative conditions, an increase in the diagnosis of genetic neurological diseases, an initial emphasis on symptomatic management, the widening scope of neurology specialty care, and a rise in hospital-based neurological treatments.

The huntington’s disease treatment market is poised for substantial growth in the upcoming years, with projections indicating it will reach $1.48 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.6%. This expansion is primarily attributed to advancements in gene therapy technologies, a rise in investment dedicated to rare disease research, an increase in orphan drug designations, wider adoption of precision medicine, and an expanding pipeline of disease-modifying therapies. Noteworthy trends during this forecast period include an intensified focus on disease-modifying treatments, the growing acceptance of gene and RNA-based therapies, the broadened application of combination therapy approaches, a greater emphasis on developing drugs specific to symptoms, and an increase in clinical trial activities for rare neurological disorders.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Huntington’s Disease Treatment Market?

The Huntington’s disease treatment market is anticipated to expand due to the rising adoption of gene therapies. These therapies involve modifying or replacing defective genes to treat or prevent illnesses at a genetic level. Their growth is propelled by advancements in precision medicine, allowing for precise targeting of genetic origins and superior results compared to conventional methods. For Huntington’s disease, gene therapies work by deactivating the faulty HTT gene, which is responsible for producing harmful proteins, thereby preventing damage to nerve cells. This approach helps to decelerate disease progression, safeguard brain function, and holds promise for sustained management. As an illustration, a report from July 2023 by the American Society of Gene & Cell Therapy (ASGCT) and Citeline indicated that the number of gene therapies in phase II increased from 247 at the end of Q1 2023 to 260 by the end of Q2, representing a 5% rise. Consequently, the increasing prevalence of gene therapies is a significant catalyst for the growth of the Huntington’s disease treatment market.

How Is The Huntington’s Disease Treatment Market Organized Into Various Segments?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Which Competitive Trends Are Impacting The Structure Of The Huntington’s Disease Treatment Market?

Major companies within the Huntington’s disease treatment market are concentrating on developing advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, to potentially enhance patient quality of life while slowing the progression of the disease. Selective VMAT2 inhibitor capsules are medications that block vesicular monoamine transporter 2, a protein involved in packaging neurotransmitters for release in the brain. These drugs help reduce neurotransmitter release, thereby assisting in the management of involuntary movements and related symptoms. For instance, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, received approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules for the treatment of chorea associated with Huntington’s disease (HD) in adults. These capsules are a once-daily oral VMAT2 inhibitor, functioning by reducing excessive dopamine signaling in the brain to help control involuntary movements. The medication is available in multiple capsule strengths and can be taken with or without food, providing a convenient dosing option for patients.

Who Are The Major Companies Operating In The Huntington’s Disease Treatment Market?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Huntington’s Disease Treatment Market?

North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Huntington’s Disease Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2026, By The Business Research Company

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the huntington’s disease treatment market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Huntington’s Disease Treatment Market Size?

The Huntington’s disease treatment market has experienced significant expansion recently. Its value is projected to rise from $0.73 billion in 2024 to $0.82 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 12.3%. This historical growth can be attributed to several factors, including heightened awareness of genetic disorders, enhanced accessibility to genetic testing, increasing investment in neurodegenerative disease research, a surge in clinical trials for experimental therapies, and an expanding pipeline of disease-modifying drugs.

The Huntington’s disease treatment market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of “$1.32 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.6%. This projected increase during the forecast period is driven by several factors, including an intensified focus on personalized medicine, greater adoption of digital health monitoring, increased regulatory backing for orphan drugs, a rising need for therapies offering symptomatic relief, and growing demand for treatments that modify the disease course. Key developments expected during this period encompass technology-driven gene silencing techniques, the advancement of cell-based therapies, the emergence of peripheral biomarkers, the incorporation of telehealth into HD care, the integration of patient-reported outcomes, and ongoing innovation in disease-modifying drugs.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

What Core Market Drivers Are Expanding The Huntington’s Disease Treatment Industry?

The growing application of gene therapies is anticipated to boost the expansion of the Huntington’s disease treatment market in the coming years. Gene therapies are medical interventions designed to modify or replace faulty genes, aiming to cure or prevent illnesses at their fundamental genetic level. As precision medicine progresses, gene therapies are gaining prominence, enabling direct targeting of genetic causes and yielding improved outcomes compared to conventional treatments. In the context of Huntington’s disease, gene therapies function by silencing the defective HTT gene, which is responsible for generating harmful proteins, thus preventing damage to nerve cells. This approach aids in slowing the disease’s progression, preserving brain function, and offers the potential for long-term management. For instance, in July 2023, according to information from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, the number of gene therapies in phase II was 247 at the end of Q1 2023, and this figure subsequently increased by 5% to reach 260 by the end of Q2. Thus, the expansion in gene therapies is a key driver for the growth of the Huntington’s disease treatment market.

What Segment Insights Are Highlighted In The Huntington’s Disease Treatment Market Report?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Which Notable Trends Are Transforming The Huntington’s Disease Treatment Market Outlook?

Companies operating within the Huntington’s disease treatment market are prioritizing the development of advanced therapies, including selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, to potentially improve patient quality of life and slow the disease’s advancement. Selective VMAT2 inhibitor capsules are medications designed to block the vesicular monoamine transporter 2, a protein involved in the packaging of neurotransmitters for release within the brain. These drugs contribute to reducing neurotransmitter release, thereby assisting in the management of involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, obtained approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules for addressing chorea associated with Huntington’s disease (HD) in adults. These capsules are a once-daily oral VMAT2 inhibitor that functions by decreasing excessive dopamine signaling in the brain to help regulate involuntary movements. The medication is offered in multiple capsule strengths and can be taken independently of food, providing a convenient dosing choice for patients.

Which Firms Are Driving Innovation Within The Huntington’s Disease Treatment Market?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

What Regional Trends Are Shaping Growth In The Huntington’s Disease Treatment Market?

North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2025, By The Business Research Company

Brain Tumor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Huntington’s Disease Treatment Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The Huntington’s disease treatment market size has experienced swift expansion in recent years. Forecasts indicate it will expand from $0.73 billion in 2024 to reach $0.82 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 12.3%. Historically, this market expansion can be ascribed to factors such as heightened awareness of genetic conditions, greater availability of genetic testing, increased funding for research into neurodegenerative diseases, a surge in clinical trials for experimental therapies, and an expanding selection of disease-modifying drug candidates.

The Huntington’s disease treatment market size is projected to experience substantial expansion over the upcoming years, reaching $1.32 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.6%. This anticipated growth during the forecast period stems from factors such as an escalating emphasis on personalized medicine, greater integration of digital health monitoring, enhanced regulatory backing for orphan drugs, increasing demand for therapies aimed at symptomatic relief, and a rising need for disease-modifying treatments. Key developments expected within this period encompass technology-driven gene silencing tools, the advancement of cell-based therapies, the emergence of peripheral biomarkers, the incorporation of telehealth into HD care, the integration of patient-reported outcomes, and ongoing innovation in disease-modifying drugs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

Which Factors And Drivers Are Influencing The Huntington’s Disease Treatment Market In 2025?

The expanding availability of gene therapies is anticipated to drive the future expansion of the Huntington’s disease treatment market. These therapies function by altering or substituting defective genes, aiming to remedy or avert conditions at their genetic origin. The development of gene therapies is progressing alongside advancements in precision medicine, allowing for precise targeting of genetic roots of diseases and yielding superior results compared to conventional approaches. For Huntington’s disease, gene therapies work by deactivating the flawed HTT gene responsible for producing detrimental proteins, thereby hindering nerve cell deterioration. This method contributes to decelerating the disease’s progression, safeguarding brain functionality, and presents a prospect for sustained management. An illustrative example, reported in July 2023 by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, showed that while 247 gene therapies were in phase II at the close of Q1 2023, this figure saw a 5% increase, reaching 260 by the conclusion of Q2. Consequently, the proliferation of gene therapies is a significant impetus behind the expansion of the Huntington’s disease treatment market.

What Are The Different Segment Classifications Within The Huntington’s Disease Treatment Market?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Which Ongoing Trends Are Expected To Shape The Huntington’s Disease Treatment Market Outlook?

Leading firms within the Huntington’s disease treatment market are concentrating on creating cutting-edge therapies, like selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the aim of enhancing patients’ quality of life and decelerating the illness’s advancement. These selective VMAT2 inhibitor capsules function as drugs that impede vesicular monoamine transporter 2, which is a protein crucial for the packaging of neurotransmitters prior to their release in the brain. By reducing neurotransmitter release, these medications assist in controlling involuntary movements and associated symptoms. As an example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, obtained approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules, intended for treating chorea linked to Huntington’s disease (HD) in adults. These capsules represent a once-daily oral VMAT2 inhibitor that functions by diminishing overactive dopamine signaling in the brain, thereby assisting in the management of involuntary movements. This medication is offered in multiple capsule strengths and can be administered with or without food, providing a practical dosing choice for patients.

Which Key Players Are Driving Competition In The Huntington’s Disease Treatment Market?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

What Are The Key Regional Factors Influencing The Huntington’s Disease Treatment Market Growth?

North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Huntington’s Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2025, By The Business Research Company

Brain Tumor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model